ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1418

Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry

Colleen Correll1, Scott Stryker2, David Collier3, Anne Dennos4, Stephen Balevic5, Thomas Phillips5 and Tim Beukelman6, 1University of Minnesota, Minneapolis, MN, 2Amgen Inc., San Francisco, CA, 3Amgen Inc., Simi Valley, CA, 4Duke University, Durham, NC, 5Duke Clinical Research Institute, Durham, NC, 6Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL

Meeting: ACR Convergence 2022

Keywords: Disease Activity, Juvenile idiopathic arthritis, Juvenile Rheumatoid Arthritis, Psoriatic arthritis, TNF-blocking Antibody

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Treatment Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Juvenile psoriatic arthritis (JPsA) constitutes ~5% of juvenile idiopathic arthritis (JIA). Several therapeutics are available for JPsA; however, given the low JPsA incidence, important efficacy and safety queries remain. We used data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry to evaluate the safety and effectiveness of etanercept (ETN) in JPsA.

Methods: Initiated in 2015, the CARRA Registry is an international registry of children with rheumatic diseases. The registry collects retrospective data at enrollment and prospective observational data approximately every 6 months at routine clinic visits and ideally at initiation of JIA medications. Data were collected from ~70 clinical sites in the US and Canada beginning 30 Jun 2015 until the data cutoff date of 2 Aug 2021. Data were analyzed for patients aged ≥ 2 to < 18 years who had a JPsA diagnosis as determined by a rheumatologist and had ever used ETN. The safety cohort included patients with observed ETN exposure following registry enrollment; the effectiveness cohort included patients with a JPsA diagnosis at registry visit ±14 days from ETN initiation. Safety outcomes assessed were rates of prespecified adverse events of special interest (AESIs) and serious adverse events (SAEs) expressed as incidence rates/100 person-years. Effectiveness outcomes assessed were change in the American College of Rheumatology-Pediatric Response (ACR-Pedi Response) 30/50/70/90/100, clinical Juvenile Arthritis Disease Activity Score-10 (cJADAS-10), and ACR provisional clinical inactive disease criteria at 6- and 12-month follow-up visits.

Results: Overall, 3,155 patients with JIA in the CARRA Registry had ETN exposure and were screened for eligibility; 226 patients had JPsA and of those, 191 met the criteria for safety analysis and 43 for effectiveness analysis. Patients in the safety cohort were predominantly White (80.6%), female (66.0%), initiated ETN at a median (IQR) age of 10 (6, 14) years, and 59.2% had concomitant use of nonbiologic DMARDs. Median (IQR) cJADAS-10 was 10 (6, 10). ETN dosing was consistent with the JIA product label; median (IQR) for patients weighing < 62.5kg was 0.8 (0.8, 0.9) mg/kg and 5/6 patients weighing >62.5kg received 50mg weekly. Patients receiving ETN had a low incidence of AESIs and SAEs (incidence rates: 0.18–0.55/100 patient-years; Table 1). ETN showed effectiveness for JPsA treatment (Table 2), with ACR30 of 80.0% and ACR100 of 46.7% at the 6-month follow-up.

Conclusion: Data in the CARRA Registry showed that ETN treatment in JPsA was effective, with low rates of AESIs and SAEs. Among other questions, further research is needed to evaluate whether a difference in ETN effectiveness in axial vs nonaxial JPsA exists.

Supporting image 1

Supporting image 2


Disclosures: C. Correll, None; S. Stryker, Amgen; D. Collier, Amgen; A. Dennos, None; S. Balevic, Purdue Pharma, UCB; T. Phillips, None; T. Beukelman, Novartis, UCB.

To cite this abstract in AMA style:

Correll C, Stryker S, Collier D, Dennos A, Balevic S, Phillips T, Beukelman T. Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/change-in-disease-activity-and-occurrence-of-adverse-events-after-initiation-of-etanercept-in-pediatric-patients-with-juvenile-psoriatic-arthritis-in-the-carra-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/change-in-disease-activity-and-occurrence-of-adverse-events-after-initiation-of-etanercept-in-pediatric-patients-with-juvenile-psoriatic-arthritis-in-the-carra-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology